EU Approves Arrowhead's REDEMPLO for Rare Fat Disorder FCS

Key Facts

In a move reflecting a major milestone for the biotech sector, Arrowhead Pharmaceuticals has received marketing authorization from the European Commission for its drug REDEMPLO (plozasiran). This approval marks the first siRNA medicine authorized for the treatment of Familial Chylomicronemia Syndrome (FCS) in adults. According to reports, the decision was driven by Phase 3 PALISADE study results, which demonstrated an 80% reduction in triglycerides and an 83% decrease in the incidence of acute pancreatitis.

This regulatory achievement comes amid intensifying competition in the rare disease space, as peers like Ionis Pharmaceuticals develop rival therapies for lipid disorders. Compared to historical clinical data in this field, REDEMPLO’s efficacy profile positions it strongly within the European market. Per market data, this authorization strengthens Arrowhead's commercial pipeline at a time when investor sentiment toward the healthcare innovation sector remains a key focus.

Version History